2478 related articles for article (PubMed ID: 12875604)
21. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
22. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Crown J
Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
24. Primary chemotherapy with docetaxel for the management of breast cancer.
Valero V
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):35-43. PubMed ID: 12108896
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
26. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
27. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Dang CT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
[TBL] [Abstract][Full Text] [Related]
28. Advances in the use of taxanes in the adjuvant therapy of breast cancer.
Nabholtz JM; Vannetzel JM; Llory JF; Bouffette P
Clin Breast Cancer; 2003 Aug; 4(3):187-92. PubMed ID: 14499011
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
Heys SD; Hutcheon AW; Sarkar TK; Ogston KN; Miller ID; Payne S; Smith I; Walker LG; Eremin O;
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S69-74. PubMed ID: 12435290
[TBL] [Abstract][Full Text] [Related]
30. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
Herceg D; Vrbanec D
Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
Hudis C
Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Gradishar WJ
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
[TBL] [Abstract][Full Text] [Related]
33. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Hong WK
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
Perez EA
Curr Oncol Rep; 2003 Jan; 5(1):66-71. PubMed ID: 12493153
[TBL] [Abstract][Full Text] [Related]
35. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
[TBL] [Abstract][Full Text] [Related]
36. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
Nabholtz JM; Tonkin K; Smylie M; Au HJ; Lindsay MA; Mackey J
Expert Opin Pharmacother; 2000 Jan; 1(2):187-206. PubMed ID: 11249542
[TBL] [Abstract][Full Text] [Related]
37. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
38. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
D'Andrea GM; Seidman AD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]